Pages with the most revisions

Jump to navigation Jump to search

Showing below up to 250 results in range #251 to #500.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

  1. What is Radon?‏‎ (2 revisions)
  2. Platelet-derived growth factor‏‎ (2 revisions)
  3. Activity‏‎ (2 revisions)
  4. Radiation modifier‏‎ (2 revisions)
  5. Radionuclides of natural origin‏‎ (2 revisions)
  6. Recovery (cellular or tissue)‏‎ (2 revisions)
  7. Beta-minus decay‏‎ (2 revisions)
  8. Retrievability‏‎ (2 revisions)
  9. Clearance level‏‎ (2 revisions)
  10. Immune system‏‎ (2 revisions)
  11. Institutional control‏‎ (2 revisions)
  12. Stakeholder‏‎ (2 revisions)
  13. Tachycardia‏‎ (2 revisions)
  14. Tissue equivalent material‏‎ (2 revisions)
  15. Dose constraint‏‎ (2 revisions)
  16. Myocardial stress test‏‎ (2 revisions)
  17. Early normal tissue responses‏‎ (2 revisions)
  18. Oversight‏‎ (2 revisions)
  19. Projected dose‏‎ (2 revisions)
  20. Radioresponsiveness‏‎ (2 revisions)
  21. Recovery responder‏‎ (2 revisions)
  22. Beta-plus decay‏‎ (2 revisions)
  23. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  24. Reversibility‏‎ (2 revisions)
  25. In vivo radiobioassay‏‎ (2 revisions)
  26. Solar particle event‏‎ (2 revisions)
  27. Cumulative dose‏‎ (2 revisions)
  28. Dose conversion coefficient‏‎ (2 revisions)
  29. Edema‏‎ (2 revisions)
  30. Worker‏‎ (2 revisions)
  31. Nuclear track detectors‏‎ (2 revisions)
  32. Excess relative risk‏‎ (2 revisions)
  33. Exposure situation‏‎ (2 revisions)
  34. Radiation safety officer‏‎ (2 revisions)
  35. Growth factor‏‎ (2 revisions)
  36. Alimentary tract transfer factor‏‎ (2 revisions)
  37. Radiosensitiser‏‎ (2 revisions)
  38. Hormones‏‎ (2 revisions)
  39. Authorization‏‎ (2 revisions)
  40. Rehabilitation of living conditions‏‎ (2 revisions)
  41. Right to know‏‎ (2 revisions)
  42. Clonogenic cells‏‎ (2 revisions)
  43. Incidence‏‎ (2 revisions)
  44. Solar wind‏‎ (2 revisions)
  45. Curie‏‎ (2 revisions)
  46. Target tissue‏‎ (2 revisions)
  47. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  48. Effect Dose 50‏‎ (2 revisions)
  49. Working level‏‎ (2 revisions)
  50. OLINDA/EXM‏‎ (2 revisions)
  51. Endogeneous excretion‏‎ (2 revisions)
  52. Particle radiance‏‎ (2 revisions)
  53. Exposure to Radon at Home‏‎ (2 revisions)
  54. Protection strategy‏‎ (2 revisions)
  55. GATA binding protein 2‏‎ (2 revisions)
  56. Radiation source‏‎ (2 revisions)
  57. Radiosensitivity, cellular‏‎ (2 revisions)
  58. Hounsfield unit‏‎ (2 revisions)
  59. Authorized limit‏‎ (2 revisions)
  60. Cardiac arrhythmias‏‎ (2 revisions)
  61. Rigidity‏‎ (2 revisions)
  62. Clonogenic survival‏‎ (2 revisions)
  63. Security‏‎ (2 revisions)
  64. Incident‏‎ (2 revisions)
  65. Intermediate level waste‏‎ (2 revisions)
  66. Cytokines‏‎ (2 revisions)
  67. Stenosis‏‎ (2 revisions)
  68. Local DRL‏‎ (2 revisions)
  69. Tolerability‏‎ (2 revisions)
  70. Medical exposure‏‎ (2 revisions)
  71. Naturally occurring radioactive material‏‎ (2 revisions)
  72. Working level month‏‎ (2 revisions)
  73. Acute radiation syndrome‏‎ (2 revisions)
  74. Alveolar-interstitial region‏‎ (2 revisions)
  75. Autoimmune disease‏‎ (2 revisions)
  76. ICRP Publication 118‏‎ (2 revisions)
  77. Cardiac valve diseases‏‎ (2 revisions)
  78. Inclusiveness‏‎ (2 revisions)
  79. Source-related‏‎ (2 revisions)
  80. Internal conversion electron‏‎ (2 revisions)
  81. LD 50/30‏‎ (2 revisions)
  82. Telangiectasia‏‎ (2 revisions)
  83. Disposal‏‎ (2 revisions)
  84. Member of the public‏‎ (2 revisions)
  85. Dose criteria‏‎ (2 revisions)
  86. Unattached fraction‏‎ (2 revisions)
  87. Necrosis‏‎ (2 revisions)
  88. Environmental exposure‏‎ (2 revisions)
  89. Patient entrance reference point‏‎ (2 revisions)
  90. Exempt waste‏‎ (2 revisions)
  91. Potential recoverability correction factor‏‎ (2 revisions)
  92. Protective action guide‏‎ (2 revisions)
  93. Adaptive response‏‎ (2 revisions)
  94. Radiation worker‏‎ (2 revisions)
  95. Radon: Units of Measure‏‎ (2 revisions)
  96. Reference air kerma‏‎ (2 revisions)
  97. Co-expertise‏‎ (2 revisions)
  98. Self-help protection‏‎ (2 revisions)
  99. Individual-related‏‎ (2 revisions)
  100. Connective tissue‏‎ (2 revisions)
  101. DRL process‏‎ (2 revisions)
  102. Storage‏‎ (2 revisions)
  103. Track structure‏‎ (2 revisions)
  104. Mendelian diseases‏‎ (2 revisions)
  105. Neurological syndrome‏‎ (2 revisions)
  106. Occupational exposure‏‎ (2 revisions)
  107. Environmental radiation protection‏‎ (2 revisions)
  108. Peak skin dose‏‎ (2 revisions)
  109. Exemption level‏‎ (2 revisions)
  110. Radioactive dispersion device‏‎ (2 revisions)
  111. Angiogenesis‏‎ (2 revisions)
  112. Hyperbaric oxygen‏‎ (2 revisions)
  113. Bioturbation‏‎ (2 revisions)
  114. Cardioverter-defibrillator‏‎ (2 revisions)
  115. ICRP Task Groups on Radiological Protection in Healthcare‏‎ (2 revisions)
  116. Individual decontamination‏‎ (2 revisions)
  117. Consequential late effects‏‎ (2 revisions)
  118. Subcutaneous tissue‏‎ (2 revisions)
  119. Low dose rate‏‎ (2 revisions)
  120. Transfer compartment‏‎ (2 revisions)
  121. Mitigation‏‎ (2 revisions)
  122. Upper reference levels‏‎ (2 revisions)
  123. Neurovascular syndrome‏‎ (2 revisions)
  124. Effective dose equivalent‏‎ (2 revisions)
  125. Pelagic‏‎ (2 revisions)
  126. Existing exposure situation‏‎ (2 revisions)
  127. Practical radiological protection culture‏‎ (2 revisions)
  128. Gastroschisis‏‎ (2 revisions)
  129. Radioactive source‏‎ (2 revisions)
  130. Habitual mouth breather‏‎ (2 revisions)
  131. Annihilation photons‏‎ (2 revisions)
  132. Hyperfractionation‏‎ (2 revisions)
  133. Reference biokinetic model‏‎ (2 revisions)
  134. Bone marrow‏‎ (2 revisions)
  135. Relocation‏‎ (2 revisions)
  136. Risk coefficient‏‎ (2 revisions)
  137. Cohort study‏‎ (2 revisions)
  138. Individual monitoring‏‎ (2 revisions)
  139. Source term‏‎ (2 revisions)
  140. DRL value‏‎ (2 revisions)
  141. Latent time/period or latency interval‏‎ (2 revisions)
  142. Low level waste‏‎ (2 revisions)
  143. Epithelium‏‎ (2 revisions)
  144. Acceptance test‏‎ (2 revisions)
  145. Qualified expert‏‎ (2 revisions)
  146. Gastrulation‏‎ (2 revisions)
  147. Radioactive substance‏‎ (2 revisions)
  148. Habitual nose breather‏‎ (2 revisions)
  149. Radon Recommendations for Authorities‏‎ (2 revisions)
  150. Hypertrophic cardiomyopathy‏‎ (2 revisions)
  151. Background dose (rate)‏‎ (2 revisions)
  152. Reference individual‏‎ (2 revisions)
  153. Remedial action‏‎ (2 revisions)
  154. ICRPædia Guide to Dose Coefficients‏‎ (2 revisions)
  155. Containment‏‎ (2 revisions)
  156. Intervention Level‏‎ (2 revisions)
  157. Substantial radiation dose level‏‎ (2 revisions)
  158. Dose-length product‏‎ (2 revisions)
  159. Transfer rate‏‎ (2 revisions)
  160. Multi-detector computed tomography‏‎ (2 revisions)
  161. Equieffective dose‏‎ (2 revisions)
  162. Percutaneous coronary intervention‏‎ (2 revisions)
  163. Expanded and aligned radiation field‏‎ (2 revisions)
  164. Prevailing circumstances‏‎ (2 revisions)
  165. Adventitious‏‎ (2 revisions)
  166. Radioactivity‏‎ (2 revisions)
  167. Radon Recommendations for Workplaces‏‎ (2 revisions)
  168. Hypoplasia‏‎ (2 revisions)
  169. Backscatter detection system‏‎ (2 revisions)
  170. Reference level‏‎ (2 revisions)
  171. Bradycardia‏‎ (2 revisions)
  172. Remediation‏‎ (2 revisions)
  173. Risk of Exposure to Radon‏‎ (2 revisions)
  174. South Atlantic anomaly‏‎ (2 revisions)
  175. Interventional procedure‏‎ (2 revisions)
  176. Detriment‏‎ (2 revisions)
  177. Lymphatic system‏‎ (2 revisions)
  178. Dose-rate effect‏‎ (2 revisions)
  179. Transforming growth factor‏‎ (2 revisions)
  180. Electron-capture decay‏‎ (2 revisions)
  181. Pericarditis‏‎ (2 revisions)
  182. Principle of application of dose limits‏‎ (2 revisions)
  183. Fluoroscopically or computed tomography guided interventions‏‎ (2 revisions)
  184. Hazard‏‎ (2 revisions)
  185. Bragg peak‏‎ (2 revisions)
  186. Repopulation‏‎ (2 revisions)
  187. Routine monitoring‏‎ (2 revisions)
  188. ICRPædia Guide to Radon‏‎ (2 revisions)
  189. Coronary heart disease‏‎ (2 revisions)
  190. Special (non-routine) monitoring‏‎ (2 revisions)
  191. Decay constant‏‎ (2 revisions)
  192. Lifetime risk‏‎ (2 revisions)
  193. Macrophage colony stimulating factor‏‎ (2 revisions)
  194. Multiplicative risk projection model‏‎ (2 revisions)
  195. Dose of record Hp (10)‏‎ (2 revisions)
  196. Electrophysiology‏‎ (2 revisions)
  197. Accreditation‏‎ (2 revisions)
  198. Genomic integrity‏‎ (2 revisions)
  199. Apoptosis‏‎ (1 revision)
  200. Ras‏‎ (1 revision)
  201. Reference phantom‏‎ (1 revision)
  202. ICRP Publication 11‏‎ (1 revision)
  203. ICRP Publication 90‏‎ (1 revision)
  204. ICRP Publication 124‏‎ (1 revision)
  205. ICRP Publication 139‏‎ (1 revision)
  206. Size-specific dose estimate‏‎ (1 revision)
  207. ICRP Publication 153‏‎ (1 revision)
  208. Specific absorbed fraction‏‎ (1 revision)
  209. ICRP Publication 28‏‎ (1 revision)
  210. Surface contamination‏‎ (1 revision)
  211. ICRP Publication 34‏‎ (1 revision)
  212. ICRP Publication 49‏‎ (1 revision)
  213. Translocation‏‎ (1 revision)
  214. Multistage carcinogenesis model‏‎ (1 revision)
  215. ICRP Publication 63‏‎ (1 revision)
  216. ICRP Publication 78‏‎ (1 revision)
  217. Elemental dose‏‎ (1 revision)
  218. Phantom‏‎ (1 revision)
  219. Exposed individuals‏‎ (1 revision)
  220. 1954 Recommendations‏‎ (1 revision)
  221. Rb‏‎ (1 revision)
  222. ICRP Publication 1‏‎ (1 revision)
  223. Baseline disease rates‏‎ (1 revision)
  224. Reference value‏‎ (1 revision)
  225. ICRP Publication 110‏‎ (1 revision)
  226. Breakpoint cluster region/abelson‏‎ (1 revision)
  227. ICRP Publication 91‏‎ (1 revision)
  228. ICRP Publication 125‏‎ (1 revision)
  229. ICRP Publication 14‏‎ (1 revision)
  230. Commissioning‏‎ (1 revision)
  231. Slice‏‎ (1 revision)
  232. ICRP Publication 154‏‎ (1 revision)
  233. Cosmic radiation‏‎ (1 revision)
  234. ICRP Publication 29‏‎ (1 revision)
  235. ICRP Publication 35‏‎ (1 revision)
  236. Threshold level‏‎ (1 revision)
  237. ICRP Publication 5‏‎ (1 revision)
  238. Dose-threshold hypothesis‏‎ (1 revision)
  239. ICRP Publication 64‏‎ (1 revision)
  240. ICRP Publication 79‏‎ (1 revision)
  241. Organ at risk‏‎ (1 revision)
  242. 1956 Recommendations‏‎ (1 revision)
  243. Principles of protection‏‎ (1 revision)
  244. Activation‏‎ (1 revision)
  245. Radiation-induced second cancer‏‎ (1 revision)
  246. Radiological attack‏‎ (1 revision)
  247. Hereditary effect‏‎ (1 revision)
  248. Reactive oxygen species‏‎ (1 revision)
  249. ICRP Publication 10‏‎ (1 revision)
  250. Reference worker‏‎ (1 revision)

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://icrpaedia.org/Special:MostRevisions"